KZIA - Kazia Therapeutics Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.0363
-0.0624 (-2.01%)
At close: 9:53AM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close3.0987
Open2.9100
Bid2.1700 x 900
Ask3.3200 x 1100
Day's Range2.9100 - 3.0730
52 Week Range2.0400 - 5.5900
Volume855
Avg. Volume3,340
Market Cap19.332M
Beta (3Y Monthly)2.80
PE Ratio (TTM)N/A
EPS (TTM)-0.9200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.22
  • Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
    PR Newswire5 days ago

    Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cancer research network sponsored by the National Cancer Institute. Alliance will launch a multi-centre phase II study to investigate the potential use of Kazia's investigational new drug, GDC-0084, alongside several other targeted cancer therapies, in the treatment of brain metastases (cancer that has spread to the brain).

  • New positive data from phase IIa trial in brain cancer patients
    PR Newswire16 days ago

    New positive data from phase IIa trial in brain cancer patients

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce new safety data from its ongoing phase IIa study of GDC-0084 in newly-diagnosed patients with glioblastoma (GBM). Licensed from Genentech in October 2016, GDC-0084 is a novel targeted therapy that inhibits the PI3K pathway, which is important in many forms of cancer and is activated in 85-90% of GBM cases. The phase II a study has determined a maximum tolerated dose (MTD) of 60mg, which is substantially higher than the 45mg dose found during Genentech's phase I study in patients with recurrent disease.

  • Kazia calls for greater awareness of the deadliest gynecological cancer in the US
    PR Newswire17 days ago

    Kazia calls for greater awareness of the deadliest gynecological cancer in the US

    SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US. In 2019, around 22,530 women will receive a new diagnosis of ovarian cancer[1] while the disease has one of the lowest survival rates of all female cancers, with only 46.5% of patients surviving five years post diagnosis[2]. Kazia's CEO, Dr James Garner said, "In 2019, more than 13,000 women will die from ovarian cancer in the US, so we are urging all women to understand all of the major signs and symptoms of ovarian cancer and seek regular check-ups with their doctors if feeling unwell.

  • PR Newswire17 days ago

    Kazia calls for greater awareness of the most lethal women's disease in Australia

    SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal women's disease in Australia. Every year, approximately 1,600 Australian women are diagnosed with ovarian cancer[1], most of them at an advanced stage. Kazia's CEO, Dr James Garner said, "Every eight hours in Australia a woman will die from ovarian cancer, so we are urging all women to understand all of the major signs and symptoms of ovarian cancer and seek regular check-ups with their doctors if feeling unwell.

  • Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
    Simply Wall St.last month

    Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Kazia Therapeutics Limited (ASX:KZA), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders ownin...

  • Kazia Presents Positive Cantrixil Phase I Data at AACR Conference
    PR Newswire2 months ago

    Kazia Presents Positive Cantrixil Phase I Data at AACR Conference

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide investors with a poster presentation summarising data from Part A of the ongoing phase I study of Cantrixil (TRX-E-002-1) in ovarian cancer. The poster will be presented at the American Association of Cancer Research (AACR) Annual Meeting in Atlanta, GA at 1:00pm EST on Monday 1 April 2019. Part A of the study was performed at five sites in the United States and Australia.

  • ACCESSWIRE2 months ago

    Edison issues ADR update on Kazia Therapeutics (KZIA)

    LONDON, UK / ACCESSWIRE / April 1, 2019 / Kazia Therapeutics (NASDAQ: KZIA) presented encouraging data from the Cantrixil Phase I study in a poster at American Association for Cancer Research (AACR) this ...

  • PR Newswire2 months ago

    Kazia to present on Cantrixil at American Association for Cancer Research (AACR) 2019 Annual Meeting

    SYDNEY , March 25, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil ...

  • Why Kazia Therapeutics Limited’s (ASX:KZA) CEO Pay Matters To You
    Simply Wall St.4 months ago

    Why Kazia Therapeutics Limited’s (ASX:KZA) CEO Pay Matters To You

    James Garner became the CEO of Kazia Therapeutics Limited (ASX:KZA) in 2016. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...

  • PR Newswire6 months ago

    Kazia Share Purchase Plan Raises A$0.8 Million, Taking Total Funds Raised to A$4.2 Million

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the Share Purchase Plan (SPP), as described in the SPP booklet dated 23 October 2018, has now been successfully completed. The SPP achieved subscriptions from eligible shareholders amounting to approximately A$0.8 million, bringing the total proceeds of this financing round to A$4.2 million (before costs). The SPP offered eligible shareholders the opportunity to apply for up to A$15,000 worth of new fully paid ordinary shares in Kazia, without incurring brokerage or other transaction costs.

  • Progress Update on GDC-0084 Program
    PR Newswire7 months ago

    Progress Update on GDC-0084 Program

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an update to shareholders regarding progress with GDC-0084, which is currently in human trials for glioblastoma and several other forms of brain cancer.

  • PR Newswire7 months ago

    Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer

    SYDNEY, Oct. 22, 2018 /PRNewswire/ -- The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia's potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain. The phase 2 clinical trial will investigate the effects of GDC-0084 in combination with the current standard of care, Herceptin (trastuzumab), in patients with HER2-positive breast cancer that has metastasised to the brain. About 10-15% of women with stage IV breast cancer develop brain metastases, according to Breastcancer.org.

  • Kazia Raises A$3.4 Million to Progress R&D Programs
    PR Newswire7 months ago

    Kazia Raises A$3.4 Million to Progress R&D Programs

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of KZA shares, primarily to sector-specialist institutional investors in Australia and internationally, at a price of A$0.38 per share. In addition, Kazia will launch a Share Purchase Plan (SPP) to allow eligible existing holders of KZA securities the opportunity to acquire new fully-paid ordinary shares on the same terms as the placement.

  • Cantrixil Phase I Study Progresses To Next Stage
    PR Newswire7 months ago

    Cantrixil Phase I Study Progresses To Next Stage

    After discussion by the Data Monitoring Committee, the study has determined a maximum tolerated dose (MTD) of 5 mg/kg, and it is expected that this dose will be used for subsequent clinical investigation.

  • PR Newswire8 months ago

    John Theurer Cancer Center Enrolls First Two Patients Nationwide for Groundbreaking Phase II Clinical Trial for Glioblastoma

    Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer, with limited available FDA-approved treatments and a median survival of only 15 months from diagnosis. About 12,500 patients in the US are diagnosed with GBM each year, including Senator John McCain, who recently passed away from the disease.

  • Kazia Releases Preliminary Cantrixil Phase I Data
    PR Newswire11 months ago

    Kazia Releases Preliminary Cantrixil Phase I Data

    NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian cancer. The phase I study of Cantrixil commenced in December 2016 at five centres in the United States and Australia. It is designed in two parts: a dose escalation component (Part A), which seeks to understand the safety profile of the drug and to determine the maximum tolerated dose (MTD), and a dose expansion cohort (Part B), which seeks to explore initial signals of efficacy.